Showing results (21-30 of 115) with videos related to

Sort By:
Pageof 12
Parkinsonism & Related Disorders|April 2, 2022
Safety and pharmacokinetics of multiple dosing with inhalable apomorphine (AZ-009), and its efficacy in a randomized crossover study in Parkinson's disease patientsEva Thijssen, Jonas M den Heijer, David Puibert, et al.
European Journal of Pain (London, England)|January 1, 2019
The ultraviolet B inflammation model: Postinflammatory hyperpigmentation and validation of a reduced UVB exposure paradigm for inducing hyperalgesia in healthy subjectsPieter S Siebenga, Guido van Amerongen, Erica S Klaassen, et al.
Scientific Reports|January 9, 2021
False negatives in GBA1 sequencing due to polymerase dependent allelic imbalanceJonas M den Heijer, Arnoud Schmitz, Peter Lansbury, et al.
Frontiers in Oncology|September 15, 2022
Integration of healthy volunteers in early phase clinical trials with immuno-oncological compoundsIgor Radanovic, Naomi Klarenbeek, Robert Rissmann, et al.
Movement Disorders Clinical Practice|November 7, 2022
A Placebo-Controlled Study to Assess the Sensitivity of Finger Tapping to Medication Effects in Parkinson's DiseaseEva Thijssen, Soma Makai-Bölöni, Emilie van Brummelen, et al.
Clinical Neurophysiology : Official Journal of the International Federation of Clinical Neurophysiology|September 25, 2018
An EEG nicotinic acetylcholine index to assess the efficacy of pro-cognitive compoundsSonja Simpraga, Huibert D Mansvelder, Geert Jan Groeneveld, et al.
Plos One|February 2, 2023
Fit for purpose of on-the-road driving and simulated driving: A randomised crossover study using the effect of sleep deprivationIngrid Koopmans, Robert-Jan Doll, Hein van der Wall, et al.
Anesthesiology|March 15, 2017
Respiratory Effects of the Nociceptin/Orphanin FQ Peptide and Opioid Receptor Agonist, Cebranopadol, in Healthy Human VolunteersAlbert Dahan, Merel Boom, Elise Sarton, et al.
Anesthesiology|June 13, 2013
Fentanyl utility function: a risk-benefit composite of pain relief and breathing responsesMerel Boom, Erik Olofsen, Meike Neukirchen, et al.
British Journal of Clinical Pharmacology|June 16, 2024
Effects of the phosphodiesterase 2 inhibitor BI 474121 on central nervous system cyclic guanosine monophosphate concentrations: Translational studiesSebastiaan van Kraaij, Rainer-Georg Goeldner, Holger Rosenbrock, et al.
Pageof 12